Home › Companies › CYTOSORBENTS CORP. › 2023-2024
At CYTOSORBENTS CORP.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 54 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 205 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 84% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CYTOSORBENTS CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CYTOSORBENTS CORP.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 6, 2024: 8 items on CYTOSORBENTS CORP.’s Form 8-K, filed June 10, 2024: 8 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore CYTOSORBENTS CORP. in the interactive database Compare manager voting policies
These tallies are CYTOSORBENTS CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Phillip P. Chan | 26,614,052 | 2,331,387 | 300,946 | -- | 10,782,068 | 92% | Not verified | — |
| Elect Director: Michael Bator | 24,889,929 | 4,075,659 | 280,797 | -- | 10,782,068 | 86% | Not verified | — |
| Elect Director: Dr. Edward R. Jones | 26,611,863 | 2,368,193 | 266,329 | -- | 10,782,068 | 92% | Not verified | — |
| Elect Director: Alan D. Sobel | 26,629,150 | 2,326,138 | 291,097 | -- | 10,782,068 | 92% | Not verified | — |
| Elect Director: Jiny Kim | 27,317,508 | 1,637,971 | 290,906 | -- | 10,782,068 | 94% | Not verified | — |
| 2. The approval of, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K | 24,276,512 | 4,672,332 | 297,541 | -- | 10,782,068 | 84% | Not verified | — |
| 3. To approve an amendment (the "Plan Amendment") to the Amended and Restated CytoSorbents Corporation 2014 Long-term Incentive Plan (the "Plan"); and | 20,042,379 | 8,960,225 | 243,781 | -- | -- | 69% | Not verified | — |
| 4. The ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 37,543,951 | 1,433,165 | 1,051,337 | -- | -- | 96% | Not verified | — |
Source: CYTOSORBENTS CORP., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
Each item below shows how the 54 asset managers that disclosed a CYTOSORBENTS CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Alan D. Sobel, CPA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Alan D. Sobel”): 26,629,150 for, 2,326,138 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 4,113,202 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Edward R. Jones, MD, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Dr. Edward R. Jones”): 26,611,863 for, 2,368,193 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 4,113,202 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Jiny Kim, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Jiny Kim”): 27,317,508 for, 1,637,971 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 4,113,202 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Michael G. Bator, MBA
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Michael Bator”): 24,889,929 for, 4,075,659 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 3,182,413 for, 930,789 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 901,950 | 0 | 0 | Against |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 20,132 | 0 | 0 | Against |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 8,707 | 0 | 0 | Against |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees to serve as directors: Phillip P. Chan, MD, PhD
CYTOSORBENTS CORP.’s own tally for this item (“Elect Director: Dr. Phillip P. Chan”): 26,614,052 for, 2,331,387 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 4,113,202 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Company's 2014 Long-Term Incentive Plan (the "2014 Long-Term Incentive Plan," or "Plan").
CYTOSORBENTS CORP.’s own tally for this item (“3. To approve an amendment (the "Plan Amendment") to the Amended and Restated CytoSorbents Corporation 2014 Long-term Incentive Plan (the "Plan"); and”): 20,042,379 for, 8,960,225 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,899,727 for, 1,213,475 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 0 | 826,407 | 0 | 0 | Against |
| Victory Capital | 0 | 364,636 | 0 | 0 | Against |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 0 | 12,848 | 0 | 0 | Against |
| BNY Mellon | 0 | 9,339 | 0 | 0 | Against |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 245 | 0 | 0 | Against |
Combines 4 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K.
CYTOSORBENTS CORP.’s own tally for this item (“2. The approval of, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item 402 of Regulation S-K”): 24,276,512 for, 4,672,332 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 901,950 | 0 | 0 | Against |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 20,132 | 0 | 0 | Against |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 8,707 | 0 | 0 | Against |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 3,182,413 for, 930,789 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Granahan Investment Management, LLC | 2,125,853 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 1,716,345 | 0 | 0 | Against |
| BlackRock | 466,961 | 94 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 173,849 | 0 | 0 | 0 | For |
| STRS OHIO | 130,819 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 75,165 | 0 | 0 | 0 | For |
| State Street | 60,493 | 0 | 0 | 0 | For |
| Texas Capital Bank Wealth Management Services Inc | 51,021 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 45,000 | 0 | 0 | 0 | For |
| Northern Trust | 37,236 | 0 | 0 | 0 | For |
| Renaissance | 34,285 | 0 | 0 | 0 | For |
| Chicago Partners Investment Group LLC | 29,494 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 0 | 29,000 | 0 | 0 | Against |
| BNY Mellon | 18,678 | 0 | 0 | 0 | For |
| SEI | 0 | 17,273 | 0 | 0 | Against |
| COUNTRY CLUB BANK | 15,225 | 0 | 0 | 0 | For |
| Vanguard | 13,865 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 6,537 | 0 | 0 | 0 | For |
| COMMERCE BANK | 0 | 5,360 | 0 | 0 | Against |
| Beacon Pointe Advisors, LLC | 5,330 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 0 | 3,825 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 3,640 | 0 | 0 | 0 | For |
| BAILARD, INC. | 0 | 2,917 | 0 | 0 | Against |
| Morton Capital Management LLC/CA | 2,000 | 0 | 0 | 0 | For |
| SECURITY NATIONAL TRUST CO | 1,800 | 0 | 0 | 0 | For |
Institutional-manager reports, all 45 managers: 3,303,286 for, 1,778,894 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of WithumSmith+Brown, PC as CytoSorbents Corporation's independent auditors to audit CytoSorbents Corporation's financial statements for the fiscal year ending December 31, 2024.
CYTOSORBENTS CORP.’s own tally for this item (“4. The ratification of the appointment of WithumSmith+Brown, PC, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 37,543,951 for, 1,433,165 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 4,113,202 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,894,386 | 0 | 0 | 0 | For |
| Neuberger Berman | 901,950 | 0 | 0 | 0 | For |
| Jackson National | 826,407 | 0 | 0 | 0 | For |
| Victory Capital | 364,636 | 0 | 0 | 0 | For |
| Fidelity | 72,892 | 0 | 0 | 0 | For |
| Morgan Stanley | 20,132 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 12,848 | 0 | 0 | 0 | For |
| BNY Mellon | 9,339 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 8,707 | 0 | 0 | 0 | For |
| BlackRock | 943 | 0 | 0 | 0 | For |
| Equitable | 717 | 0 | 0 | 0 | For |
| Guggenheim | 245 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 54,306,415 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.49% |
| 2 | Neuberger Berman | 1.66% |
| 3 | Jackson National | 1.52% |
| 4 | Victory Capital | 0.67% |
| 5 | Fidelity | 0.13% |
| 6 | Morgan Stanley | 0.04% |
| 7 | WILSHIRE MUTUAL FUNDS INC | 0.02% |
| 8 | BNY Mellon | 0.02% |
| 9 | TRUST FOR PROFESSIONAL MANAGERS | 0.02% |
| 10 | BlackRock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Granahan Investment Management, LLC | 3.91% |
| 2 | Neuberger Berman | 3.16% |
| 3 | BlackRock | 0.86% |
| 4 | CIBC Private Wealth Group LLC | 0.32% |
| 5 | STRS OHIO | 0.24% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 0.14% |
| 7 | State Street | 0.11% |
| 8 | Texas Capital Bank Wealth Management Services Inc | 0.09% |
| 9 | STIFEL NICOLAUS & CO INC \MO\ | 0.08% |
| 10 | Northern Trust | 0.07% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Nogales | 7.40% | DEF14A |
| Thomas A. Satterfield, Jr. | 7.36% | 13G |
| Avenue Capital Management II, L.P. | 6.91% | 13G |
| Waltham | 6.66% | DEF14A |
| Milwaukee | 5.99% | DEF14A |
| AVENIR CORP | 5.70% | 13G |
| Alexandria | 5.62% | DEF14A |
| Skylands Capital, LLC | 5.53% | 13G |
| Vanguard Group | 4.06% | 13F |
| Phillip P. Chan, MD, PhD | 2.44% | DEF14A |
Percentages above are of 54,306,415 shares outstanding, as reported by CYTOSORBENTS CORP. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTOSORBENTS CORP.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CYTOSORBENTS CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025.
proxyvotesnow.com, “CYTOSORBENTS (CTSO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytosorbents-corp/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.